Viridian Therapeutics, Inc.
VRDN
$12.38
-$0.43-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.01% | -3.96% | -18.00% | -33.89% | 27.40% |
| Total Depreciation and Amortization | 408.70% | -97.53% | 554.93% | -2.07% | -58.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.31% | 16.22% | -33.66% | -5.74% | -64.48% |
| Change in Net Operating Assets | -3,111.96% | -84.50% | -73.33% | 324.45% | -188.28% |
| Cash from Operations | -26.35% | -8.31% | -47.00% | -1.85% | -19.01% |
| Capital Expenditure | 24.56% | 61.09% | -181.73% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 259.47% | 25.57% | -235.91% | 143.40% | 15.69% |
| Cash from Investing | 259.04% | 25.69% | -236.61% | 143.33% | 15.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -74.43% | -84.34% | 111,888.10% | -99.89% | 39.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 84.20% | 91.35% | -14,755.88% | 99.02% | 12.07% |
| Cash from Financing | -74.07% | -85.50% | 226,773.15% | -99.94% | -10.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 116.50% | -208.71% | 478.12% | 243.27% | -27.55% |